Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2008 Oct 10.

Published in final edited form as: Vaccine. 2007 Aug 6;25(41):7247–7260. doi: 10.1016/j.vaccine.2007.07.038

Table 3.

Vaginal antibody levels specific for TbpB detected by ELISA^a

	Day 28^b		Day 63^c
Immunization
	IgA	IgG	IgA	IgG
NB-Ctb (IN/IP)	0.4 ×/÷ 4.4	0	0.5 ×/÷ 3.0	7.1 ×/÷ 3.4
NB-L2-Ctb (IN/IP)	<0.1^d	0	0.6 ×/÷ 5.3	10.8 ×/÷ 1.7
NB-L2-Ctb (s.c./ IP)	0	5.8 ×/÷ 3.5^e	0.7 ×/÷ 3.8^f	12.8 ×/÷ 1.3^f

^a

Data are expressed as the geometric mean of the percentage (specific antibody/total antibody) ×/÷ standard deviation.

^b

Day 28 is 7 days after final IN prime.

^c

Day 63 is 7 days after final boost.

^d

Only two mice had detectable TbpB-specific antibodies.

^e

Only three mice had detectable TbpB-specific antibodies.

^f

n = 4.